Visual Pathways, Inc. ("VPI") develops, manufactures and markets diagnostic medical devices to address two critical and mounting issues in global vision care:
- The increasing prevalence of vision loss and blindness related to the diabetes epidemic and aging population; and,
- The need to simultaneously drive down healthcare costs by increasing the emphasis on preventive medicine in vision care through automated, rapid screening of aging and diabetic populations and to enable earlier detection and treatment intervention in medical conditions that impair vision and cause blindness. This effort relates to the Company's mission…Preserving vision. Preventing blindness™.
The markets for VPI's products are growing rapidly worldwide and are expected to continue to grow in excess of 15% annually for the foreseeable future. There are several fundamental reasons for this; aging and diabetes are the major drivers of vision loss and blindness.
- There is an epidemic rise in diabetes worldwide. Nearly 24 million persons are affected in the United States and that number is expected to double by the year 2020; there are more than 250 million people with diabetes worldwide.
- The aging global population is "profound" and "irreversible", according to a 2007 United Nations report. In 2000 approximately 605 million people were over age 60; by 2050 there will be approximately 2 billion people over age 60.
- Diabetic Retinopathy (DR) is the leading cause of preventable blindness in working age people, worldwide.
- Age Related Macular Degeneration (ARMD) is the leading cause of blindness in people over age 60.
- There is a worldwide shortage of skilled medical personnel at all levels, further exacerbating timely delivery of medical care related to diabetes and aging, particularly in rural and remote areas.
- Ongoing interest in and adoption of telemedicine as an emerging tool for bring vision care to rural and other underserved areas, as has been done in radiology and cardiology, creating new markets within the vision care industry for an easy to use retinal imaging system (fundus camera) such as the ARIS™, for acquisition of high quality retinal images by relatively unskilled people. Its companion product, the RSVP™ (Remote Stereo Viewing Platform), can be linked to the ARIS via the Internet for remote, hands free stereo viewing of the ARIS high resolution images by a vision care specialist.
Automation resulting in greater precision
The ARIS™ automates essentially the entire procedure for acquiring high-quality retinal images. At the start of the imaging procedure, the operator sees an image of the patient's pupil on the monitor and, using a mouse, moves the image until it is roughly centered. From that point on, the ARIS™ illuminates, then automatically completes and maintains alignment and focus, adjusts the light exposure and acquires a pair of stereo images. Typically it requires less than 15 seconds to obtain infrared, red-free and color images…all in stereo.
Patient Comfort
With the ARIS™, patient comfort is dramatically increased. The ARIS™ uses infrared illumination for the pupil focus procedure and for monochrome imaging. Most patients do not experience discomfort due to the visible light flashes during the imaging process. For color imaging, colored light is used, but at much lower intensity than in existing fundus cameras. For a large percentage of the patient population, no dilation of pupils is required for acquiring images of a single field on the retina. For multiple field imaging, most clinicians will dilate the pupils as a matter of good clinical practice.